Pluralitas non est ponenda sine necessitate.
— William of Occam, 14th century
Plurality must not be posited without necessity.
Although we've all been thought to try and make it simple under a single wonderful diagnosis, I like Hickam's dictum:
Hickam’s dictum:
“A patient can have as many diagnoses as he darn well pleases."
Occam’s Razor versus Saint’s Triad
n engl j med 350;6 www.nejm.org february 5, 2004
http://www.nejm.org/doi/pdf/10.1056/NEJMcps031794
An online resource for medical professionals, trainees and students.
Tuesday, October 12, 2010
Monday, August 9, 2010
Tuesday, June 1, 2010
Evidence Based Medicine
Contains lectures in powerpoint format, CAT maker, and an EBM library.

screenshots:

After the forms are filled up, the output can be saved in several formats (txt, html)
screenshots:
Monday, May 3, 2010
32nd PSMID Annual Convention


32nd PSMID Annual Convention
PSMID Leveling Up!
Tips, Tools and Tricks to
Track Infectious Diseases (4T's at 40)
November 24-26, 2010
Crowne Plaza Galleria Manila
Quezon City
Download Booklet
Download Program-at-a-Glance
PCP 40th Annual Convention
Thursday, March 4, 2010
29th Annual Chest Convention
----------
Philippine Clinical Practice Guidelines on the Diagnosis, Empiric Management, and Prevention of Community acquired pneumonia in Immunocompetent Adults 2010
-----------
Idiopathic pulmonary fibrosis
American Thoracic Society/European RespiratorySociety International Multidisciplinary Consensus
Classification of the Idiopathic Interstitial Pneumonias
American Thoracic Society
Am J Respir Crit Care Med Vol 165. pp 277–304, 2002
My approach to interstitial lung disease using clinical, radiological and histopathological patterns
- K O Leslie
-----------
Newer fluoroquinolones mask tuberculosis
European Respiratory Journal March 2010; 35:606-613
-------------
Asian Perspectives in the New Decade
Standards and Innovations in Pulmonary Medicine
Sofitel Philippine Plaza
March 3-5, 2010
-- Post From My iTouch
Sunday, February 21, 2010
New Guideline for Intra-Abdominal Infection Released
http://news.idsociety.org/idsa/issues/2010-01-31/2.html
IDSA guideline for Intra-abdominal infection released January 2010
IDSA guideline for Intra-abdominal infection released January 2010
Monday, January 18, 2010
TREAT
Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
Tuesday, January 12, 2010
Gold Spirometry
GOLD SPIROMETRIC CRITERIA FOR COPD SEVERITY1
I: Mild COPD
• FEV1/FVC < 0.7
• FEV1 ≥ 80% predicted
At this stage, the patient may not be aware that their lung function is abnormal.
II: Moderate COPD
• FEV1/FVC < 0.7
• 50% ≤ FEV1 < 80%
predicted Symptoms usually progress at this stage, with shortness of breath typically developing on exertion.
III: Severe COPD
• FEV1/FVC < 0.7
• 30% ≤ FEV1 < 50% predicted
Shortness of breath typically worsens at this stage and often limits patients’ daily activities. Exacerbations are especially seen beginning at this stage.
IV: Very Severe COPD
• FEV1/FVC < 0.7
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure
At this stage, quality of life is very appreciably impaired and exacerbations may be life-threatening.
GOLD
I: Mild COPD
• FEV1/FVC < 0.7
• FEV1 ≥ 80% predicted
At this stage, the patient may not be aware that their lung function is abnormal.
II: Moderate COPD
• FEV1/FVC < 0.7
• 50% ≤ FEV1 < 80%
predicted Symptoms usually progress at this stage, with shortness of breath typically developing on exertion.
III: Severe COPD
• FEV1/FVC < 0.7
• 30% ≤ FEV1 < 50% predicted
Shortness of breath typically worsens at this stage and often limits patients’ daily activities. Exacerbations are especially seen beginning at this stage.
IV: Very Severe COPD
• FEV1/FVC < 0.7
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure
At this stage, quality of life is very appreciably impaired and exacerbations may be life-threatening.
GOLD
Saturday, January 9, 2010
JUPITER TRIAL
JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial)
http://www.brighamandwomens.org/preventivemedicine/Research/Circv108p2292.pdf
http://www.brighamandwomens.org/preventivemedicine/Research/Circv108p2292.pdf
Surviving Sepsis Campaign Statement on Glucose Control in
Severe Sepsis (June 2009*)
There is insufficient information from randomized controlled trials to
determine the optimal target range of blood glucose in the severely septic
patient. (1) The NICE-SUGAR trial is the largest most compelling study to
date on glucose control in ICU patients given its inclusion of multiple ICUs
and hospitals, and a more general patient population. (2) Based on the
results of this trial, we recommend against intravenous insulin therapy
titrated to keep blood glucose in the normal range (80-110 mg/dl) in
patients with severe sepsis. It is clear that attempts to normalize blood
glucose with IV insulin during critical illness results in higher rates of
hypoglycemia. (1,3) Until additional information is available, teams
seeking to implement glucose control should consider initiating insulin
therapy when blood glucose levels exceed 180 mg/dL with a goal blood
glucose approximating 150 mg/dl as was observed in the beneficial arm
of the NICE-SUGAR trial.
1) Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ,
Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S,
Talmor D. Intensive insulin therapy and mortality among critically ill
patients: a meta-analysis including NICE-SUGAR study data. CMAJ.
2009 Apr 14;180(8):799-800.
2) NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair
D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR,
Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell
I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive
versus conventional glucose control in critically ill patients. N Engl J
Med. 2009 Mar 26;360(13):1283-97. Epub 2009 Mar 24
3) Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose
control in critically ill adults: A meta-analysis. JAMA 2008;300:933–
44
*This revised recommendation has been issued by Surviving Sepsis Campaign (SSC)
Guidelines Committee Subgroup for Glucose Control; R. Phillip Dellinger, MD, FCCM, the 2008
SSC Guidelines Chair; and the SSC Executive Committee. Posted on the SSC Web site and list
serve 6/12/2009.
Tuesday, January 5, 2010
Rifle Criteria
Sunday, January 3, 2010
The GOLD global strategy for the diagnosis, management, and prevention of COPD is presented in its guideline documents, which are freely available on the GOLD Website
Saturday, January 2, 2010
Subscribe to:
Posts (Atom)